Six analysts give Karyopharm stock a USD 11.50 consensus target
Published on 10/15/2026 at 20:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget and reporting date
- MarketBeat listed a USD 11.50 consensus target from six analysts on October 14, 2026.
- Karyopharm guided to USD 130.00 million to USD 150.00 million in full-year 2026 revenue.
- Karyopharm stock costs EUR 0.29 at Lang & Schwarz on October 15, 2026 at 8:35 p.m. CEST.
- Karyopharm's next earnings date is November 3, 2026.
Six analysts give Karyopharm Therapeutics stock a USD 11.50 consensus target, according to MarketBeat on October 14, 2026. Against the Nasdaq price of USD 0.32, that target stands 3,493.75 percent higher. Karyopharm stock was trading at EUR 0.29 at Lang & Schwarz on October 15, 2026 at 8:35 p.m. CEST.
Revenue guidance sets the scale
Karyopharm expects total revenue of USD 130.00 million to USD 150.00 million for full-year 2026, according to Simply Wall St, which lists the guidance as reaffirmed on August 13, 2026. The range covers U.S. XPOVIO net product revenue plus licensing, royalty and milestone revenue from partners.
Price position remains extreme
The Nasdaq quote was USD 0.32 at 2:41 p.m. EDT on October 15, 2026, up 1.94 percent on the day. MarketBeat listed a 52-week range of USD 0.32 to USD 10.99 and a volume of 2.04 million shares against an average of 1.06 million shares on October 14, 2026. The stock was down 95.50 percent from its level at the start of 2026, according to the same source.
Valuation and next reporting date
Karyopharm's market capitalization was USD 7.30 million, while its trailing P/E was negative 0.02 and its dividend yield was zero in the October 15, 2026 quote. ToAlpha lists November 3, 2026 as the next earnings date. Karyopharm's investor-relations page describes the company as a commercial-stage pharmaceutical business focused on cancer therapies and XPO1 inhibition.
Comparison with peers
Karyopharm Therapeutics: plus 1.94 percent, P/E -0.02, market capitalization USD 7.3 million
Marker Therapeutics (Nasdaq, USD): plus 3.58 percent, P/E -1.99, market capitalization USD 15.4 million
Cerenome (Nasdaq, USD): plus 10.06 percent, P/E -0.42, market capitalization USD 14.1 million
Dates and market context
The next earnings date is November 3, 2026. The figures leave Karyopharm with a narrow valuation base and a large gap between its Nasdaq quotation and the consensus target.
Stock price in euros
Karyopharm stock was trading at EUR 0.29 at Lang & Schwarz on October 15, 2026 at 8:35 p.m. CEST. The Nasdaq quote was USD 0.32 at 2:41 p.m. EDT on the same date.
The further course of trading is shown by the continuously updated real-time quote of Karyopharm Therapeutics stock.
Karyopharm Therapeutics stock facts
- Company: Karyopharm Therapeutics Inc.
- ISIN: US48576U2050
- Ticker: KPTI
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 8:35 p.m. CEST): EUR 0.29
- Market capitalization: USD 7.3 million (as of October 15, 2026)
- 52-week range: USD 0.32-10.99 (as of October 14, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
